Apratoxin A vs SNX-482
Head-to-head comparison of Apratoxin A (Apratoxin A) and SNX-482 (SNX-482 peptide from Hysterocrates gigas venom) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Apratoxin A | SNX-482 |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | Apratoxin A | SNX-482 peptide from Hysterocrates gigas venom |
| Molecular Weight | N/A | 4,300 Da |
| Half-Life | N/A | Minutes to hours |
| Amino Acids | N/A | 41 |
| Typical Dose | N/A in humans; nanomolar in vitro | 0.01-1 nmol intrathecal|1-100 nM in vitro|single-dose electrophysiology studies |
| Route | Intraperitoneal / Intravenous (preclinical) | Intrathecal |
| Purity | ≥98% | ≥98% |
| Studies Count | 140 | 85 |
| Research Status | Pre-clinical | Pre-clinical |
Apratoxin A Benefits
- ✓antineoplastic
- ✓anti-angiogenic
- ✓Sec61 inhibition
- ✓anti-proliferative
SNX-482 Benefits
- ✓Cav2.3 blockade
- ✓synaptic transmission studies
- ✓excitability mapping
- ✓pain and epilepsy research
Apratoxin A Dosing
preclinical in vitro nanomolar use|animal studies only|no human dosing established
SNX-482 Dosing
Patch-clamp Cav2.3 assays|Intrathecal neurophysiology studies|Acute channel-blockade experiments
Apratoxin A Side Effects
- ⚠hepatotoxicity
- ⚠general cytotoxicity
- ⚠GI toxicity
SNX-482 Side Effects
- ⚠Ataxia at high exposure
- ⚠off-target calcium-channel block
- ⚠cardiovascular effects in animal models
Research Overview
Apratoxin A
Apratoxin A is a well-studied lead compound for targeting secretory and membrane protein biogenesis in cancer cells. Medicinal chemistry programs around apratoxins focus on improving selectivity and reducing hepatotoxicity while preserving potency.
SNX-482
SNX-482 has been used to dissect R-type calcium currents in neurons and endocrine cells, and to map the role of Cav2.3 in excitability. Its selectivity profile has made it a standard research reagent in channel pharmacology.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.